blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3381445

EP3381445 - AQUEOUS FORMULATION OF ANTIBODY STABLISED BY ANTIOXIDANTS FOR PARENTERAL ADMINISTRATION [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  30.08.2024
Database last updated on 20.09.2024
FormerThe patent has been granted
Status updated on  22.09.2023
FormerGrant of patent is intended
Status updated on  09.05.2023
FormerExamination is in progress
Status updated on  07.04.2020
FormerRequest for examination was made
Status updated on  19.07.2019
FormerThe application has been published
Status updated on  31.08.2018
Most recent event   Tooltip30.08.2024Lapse of the patent in a contracting state
New state(s): MC		published on 02.10.2024 [2024/40]
30.08.2024No opposition filed within time limitpublished on 02.10.2024 [2024/40]
Applicant(s)For all designated states
Amgen Inc.
One Amgen Center Drive
Thousand Oaks, California 91320-1799 / US
[2018/40]
Inventor(s)01 / SLOEY, Christopher, James
5611 Foxwood Drive, Apartment C
Oak Park, CA California 91377 / US
02 / KO, Jason
438 East Gainsborough Road
Thousand Oaks, CA California 91360 / US
03 / LI, Tiansheng
160 Via Fiesta Street
Newbury Park, CA California 91320 / US
 [2018/40]
Representative(s)J A Kemp LLP
80 Turnmill Street
London EC1M 5QU / GB
[2023/43]
Former [2018/40]J A Kemp
14 South Square
Gray's Inn
London WC1R 5JJ / GB
Application number, filing date18167567.913.11.2008
[2018/40]
Priority number, dateUS20070988354P15.11.2007         Original published format: US 988354 P
[2018/40]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report 
No.:EP3381445
Date:03.10.2018
Language:EN
[2018/40]
Type: A3 Search report 
No.:EP3381445
Date:16.01.2019
Language:EN
[2019/03]
Type: B1 Patent specification 
No.:EP3381445
Date:25.10.2023
Language:EN
[2023/43]
Search report(s)(Supplementary) European search report - dispatched on:EP19.12.2018
ClassificationIPC:A61K9/00, A61K38/18, A61K38/19, A61K39/395
[2018/40]
CPC:
A61K47/12 (EP,US); A61K38/1816 (EP,US); A61K39/3955 (US);
A61K39/39591 (EP,US); A61K47/22 (EP,US); A61K9/0019 (EP,US);
A61P7/00 (EP) (-)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2019/34]
Former [2018/40]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:WÄSSRIGE ANTIKÖRPERFORMULIERUNG MIT STABILISIERUNG DURCH ANTIOXIDANTIEN ZUR PARENTERALEN VERABREICHUNG[2018/40]
English:AQUEOUS FORMULATION OF ANTIBODY STABLISED BY ANTIOXIDANTS FOR PARENTERAL ADMINISTRATION[2018/40]
French:FORMULATION AQUEUSE D'ANTICORPS STABILISÉE PAR DES ANTIOXYDANTS POUR ADMINISTRATION PARENTÉRALE[2018/40]
Examination procedure16.07.2019Examination requested  [2019/34]
16.07.2019Date on which the examining division has become responsible
01.11.2019Amendment by applicant (claims and/or description)
14.04.2020Despatch of a communication from the examining division (Time limit: M06)
18.11.2020Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time
27.01.2021Reply to a communication from the examining division
01.02.2023Despatch of a communication from the examining division (Time limit: M02)
31.03.2023Reply to a communication from the examining division
10.05.2023Communication of intention to grant the patent
19.09.2023Fee for grant paid
19.09.2023Fee for publishing/printing paid
19.09.2023Receipt of the translation of the claim(s)
Parent application(s)   TooltipEP08849496.8  / EP2219602
Opposition(s)26.07.2024No opposition filed within time limit [2024/40]
Request for further processing for:The application is deemed to be withdrawn due to failure to reply to the examination report
27.01.2021Request for further processing filed
27.01.2021Full payment received (date of receipt of payment)
Request granted
05.02.2021Decision despatched
The application is deemed to be withdrawn due to failure to reply to the Extended European Search Report/Written Opinion of the International Searching Authority/International Preliminary Examination Report/Supplementary international search report/Supplementary European search report
01.11.2019Request for further processing filed
01.11.2019Full payment received (date of receipt of payment)
Request granted
12.11.2019Decision despatched
Fees paidRenewal fee
16.04.2018Renewal fee patent year 03
16.04.2018Renewal fee patent year 04
16.04.2018Renewal fee patent year 05
16.04.2018Renewal fee patent year 06
16.04.2018Renewal fee patent year 07
16.04.2018Renewal fee patent year 08
16.04.2018Renewal fee patent year 09
16.04.2018Renewal fee patent year 10
14.11.2018Renewal fee patent year 11
14.11.2019Renewal fee patent year 12
13.11.2020Renewal fee patent year 13
21.10.2021Renewal fee patent year 14
22.11.2022Renewal fee patent year 15
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipAT25.10.2023
CZ25.10.2023
DK25.10.2023
EE25.10.2023
HR25.10.2023
LT25.10.2023
LV25.10.2023
MC25.10.2023
NL25.10.2023
PL25.10.2023
RO25.10.2023
SE25.10.2023
SK25.10.2023
LU13.11.2023
BG25.01.2024
NO25.01.2024
GR26.01.2024
IS25.02.2024
PT26.02.2024
[2024/40]
Former [2024/36]AT25.10.2023
CZ25.10.2023
DK25.10.2023
EE25.10.2023
HR25.10.2023
LT25.10.2023
LV25.10.2023
NL25.10.2023
PL25.10.2023
RO25.10.2023
SE25.10.2023
SK25.10.2023
LU13.11.2023
BG25.01.2024
NO25.01.2024
GR26.01.2024
IS25.02.2024
PT26.02.2024
Former [2024/35]AT25.10.2023
CZ25.10.2023
DK25.10.2023
EE25.10.2023
HR25.10.2023
LT25.10.2023
LV25.10.2023
NL25.10.2023
PL25.10.2023
RO25.10.2023
SE25.10.2023
LU13.11.2023
BG25.01.2024
NO25.01.2024
GR26.01.2024
IS25.02.2024
PT26.02.2024
Former [2024/34]AT25.10.2023
DK25.10.2023
EE25.10.2023
HR25.10.2023
LT25.10.2023
LV25.10.2023
NL25.10.2023
PL25.10.2023
SE25.10.2023
LU13.11.2023
BG25.01.2024
NO25.01.2024
GR26.01.2024
IS25.02.2024
PT26.02.2024
Former [2024/33]AT25.10.2023
DK25.10.2023
HR25.10.2023
LT25.10.2023
LV25.10.2023
NL25.10.2023
PL25.10.2023
SE25.10.2023
BG25.01.2024
NO25.01.2024
GR26.01.2024
IS25.02.2024
PT26.02.2024
Former [2024/26]AT25.10.2023
HR25.10.2023
LT25.10.2023
LV25.10.2023
NL25.10.2023
PL25.10.2023
SE25.10.2023
BG25.01.2024
NO25.01.2024
GR26.01.2024
IS25.02.2024
PT26.02.2024
Former [2024/25]AT25.10.2023
HR25.10.2023
LT25.10.2023
NL25.10.2023
PL25.10.2023
SE25.10.2023
BG25.01.2024
NO25.01.2024
GR26.01.2024
IS25.02.2024
PT26.02.2024
Former [2024/24]AT25.10.2023
HR25.10.2023
LT25.10.2023
NL25.10.2023
SE25.10.2023
BG25.01.2024
NO25.01.2024
GR26.01.2024
IS25.02.2024
PT26.02.2024
Former [2024/23]AT25.10.2023
LT25.10.2023
NL25.10.2023
BG25.01.2024
GR26.01.2024
IS25.02.2024
PT26.02.2024
Former [2024/21]LT25.10.2023
NL25.10.2023
BG25.01.2024
GR26.01.2024
IS25.02.2024
Former [2024/20]NL25.10.2023
GR26.01.2024
IS25.02.2024
Former [2024/17]NL25.10.2023
Documents cited:Search[XI]WO02103029  (CLEARANT INC [US], et al) [X] 1,12,14,15 * page 14, paragraph l - page 15, paragraph l * * page 19, paragraph 3 - page 21, paragraph 1 * * page 21, line 23 * [I] 5,13;
 [X]WO2007037795  (AMGEN INC [US], et al) [X] 1,4,12-15 * claims, esp. claims 19-22; page 14, line 1; page 8, paragraph 1; claims 1,4,11-18 *;
 [T]  - WANG W ET AL, "ANTIBODY STRUCTURE, INSTABILITY, AND FORMULATION", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN CHEMICAL SOCIETY AND AMERICAN PHARMACEUTICAL ASSOCIATION, US, (20070101), vol. 96, no. 1, doi:10.1002/JPS.20727, ISSN 0022-3549, pages 1 - 26, XP009084505 [T] * page 5, column l, paragraph 1 * * page 8, column l, paragraph l - column r, paragraph 1 * * page 13, column l, paragraph l - column r, paragraph 1 * * page 14, column l, paragraph l - column r, paragraph 3 * * page 16, column r, paragraph 3 * * page 21, column l, paragraph 1 *

DOI:   http://dx.doi.org/10.1002/jps.20727
 [XI]  - GUPTA SUPRIYA ET AL, "Development of a multidose formulation for a humanized monoclonal antibody using experimental design techniques", AAPS PHARMSCI, SPRINGER NEW YORK, NEW YORK, (20030404), vol. 5, no. 2, doi:10.1208/PS050208, pages 1 - 9, XP035718636 [X] 1,3,9,12-15 * page 1, column r, paragraph l - page 2, column l, paragraph 1 * * page 2, column l, paragraph 3 * * page 5, column l, paragraph 2 - column r, paragraph 1; table 3 * [I] 2

DOI:   http://dx.doi.org/10.1208/ps050208
 [XI]  - LAM X M ET AL, "ANTIOXIDANTS FOR PREVENTION OF METHIONINE OXIDATION IN RECOMBINANT MONOCLONAL ANTIBODY HER2", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN CHEMICAL SOCIETY AND AMERICAN PHARMACEUTICAL ASSOCIATION, US, (19971101), vol. 86, no. 11, doi:10.1021/JS970143S, ISSN 0022-3549, pages 1250 - 1255, XP008038003 [X] 1,9,10,12-15 * page 1251; table 1 * * page 1254, column l, paragraph l - page 1255, column r, paragraph 1; figures 4,5 * [I] 4

DOI:   http://dx.doi.org/10.1021/js970143s
 [XI]  - DAUGHERTY A L ET AL, "Formulation and delivery issues for monoclonal antibody therapeutics", ADVANCED DRUG DELIVERY REVIEWS, ELSEVIER, AMSTERDAM, NL, vol. 58, no. 5-6, doi:10.1016/J.ADDR.2006.03.011, ISSN 0169-409X, (20060807), pages 686 - 706, (20060807), XP024892149 [X] 1,9,10,12-15 * page 688, column l, paragraph 2 - column r, paragraph 2 * * page 690, column l, paragraph l - page 691, column l, paragraph 2 * * page 697; table 1 * [I] 4

DOI:   http://dx.doi.org/10.1016/j.addr.2006.03.011
 [A]  - POTIER ET AL, "Gallic esters of sucrose as a new class of antioxidants", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, (19990423), vol. 40, no. 17, ISSN 0040-4039, pages 3387 - 3390, XP022502864 [A] 1,12,15 * the whole document *

DOI:   http://dx.doi.org/10.1016/S0040-4039(99)00496-7
 [A]  - ABDELWAHED ET AL, "Study of antimutagenic and antioxidant activities of Gallic acid and 1,2,3,4,6-pentagalloylglucose from Pistacia lentiscus", CHEMICO-BIOLOGICAL INTERACTIONS, ELSEVIER SCIENCE IRLAND, IR, (20061222), vol. 165, no. 1, ISSN 0009-2797, pages 1 - 13, XP005813189 [A] 1,12,15 * the whole document *

DOI:   http://dx.doi.org/10.1016/j.cbi.2006.10.003
by applicantUS4703008
 EP0404097
 WO9105867
 WO9110741
 WO9117271
 WO9201047
 WO9311161
 WO9505465
 US5441868
 US5547933
 WO9634096
 WO9638557
 US5618698
 US5621080
 US5686292
 US5756349
 WO9824893
 US5767078
 US5773569
 US5789554
 US5830851
 US5856298
 US5955422
 US5986047
 WO9966054
 US6030086
 WO0024893
 WO0024782
 WO0061637
 WO0136489
 US6310078
 WO0181405
 WO0214356
 WO0219963
 WO0220034
 US6391633
 WO0249673
 US6468529
 US2002155998
 WO02085940
 US2002199213
 WO03002713
 US2003023586
 US2003031667
 WO03029291
 WO03030833
 US2003077753
 US2003082749
 WO03041600
 US6583272
 US2003118592
 US6586398
 WO03055526
 US2003133939
 WO03057134
 WO03059951
 US2003138421
 US2003143202
 WO03084477
 US2003194404
 US2003195156
 US2003215444
 WO03094858
 US2003229023
 US2003235582
 WO2004002417
 WO2004002424
 US2004009902
 WO2004009627
 US2004018191
 WO2004018667
 WO2004024761
 US2004071694
 US2004071702
 WO2004033651
 WO2004035603
 US2004086503
 US2004091961
 US2004097712
 WO2004043382
 US6750369
 US6756480
 WO2004058988
 US2004143857
 US2004157293
 US2004175379
 US2004175824
 US2004181033
 US6803453
 US2004202655
 US2004229318
 US2004228859
 WO2004101600
 WO2004101606
 WO2004101611
 WO2004106373
 US2004248815
 US6835809
 US2004266690
 US2004265307
 WO2005001025
 WO2005001136
 US2005004353
 US2005008642
 US2005019914
 US2005026834
 US2005037421
 WO2005016970
 WO2005017107
 WO2005021579
 WO2005025606
 US2005074821
 WO2005032460
 US2005084906
 US2005089932
 US2005096461
 US2005107297
 US2005107591
 WO2005047331
 US2005112694
 US6900292
 US2005118643
 WO2005051327
 US2005124045
 US2005124564
 US2005137329
 US2005136049
 US2005136063
 US2005142642
 US2005143292
 WO2005058967
 WO2005063808
 WO2005063809
 US2005153879
 US6919426
 US2005158822
 US2005158832
 WO2005070451
 US2005170457
 US2005181359
 US2005181482
 US2005186203
 US2005192211
 WO2005081687
 WO2005084711
 US2005202538
 WO2005092369
 US2005227289
 WO2005100403
 WO2005103076
 US2005244409
 US2005244408
 US2005249728
 WO2006002646
 WO2006013472
 US2006040858
 US2006040358
 WO2006029094
 US7030226
 US2006088906
 US7037498
 WO2006050959
 US2006111279
 US2006135431
 US7084245
 WO2006081171
 US7153507
 WO2006138729
 WO2007000328
 WO2007011941
 WO2007012614
 US7217689
 US2007110747
 US7220410
    - MANNING et al., Pharmaceutical Research, (19890000), vol. 6
    - WANG; KOWAL, J. Parenteral Drug Association, (19800000), vol. 34, page 452
    - AVIS et al., Pharmaceutical Dosage Forms: Parenteral Medications, (19920000), vol. 1
    - ANDREWS, J. Antimicrobial Chemotherapy, (20010000), vol. 48, no. 1, pages 5 - 16
    - JONES et al., Nature, (19860000), vol. 321, page 522 525
    - MORRISON et al., Proc. Natl. Acad. Sci., U.S.A., (19840000), vol. 81, page 6851 6855
    - MORRISON; OI, Adv. Immunol., (19880000), vol. 44, pages 65 - 92
    - VERHOEYER et al., Science, (19880000), vol. 239, page 1534 1536
    - PADLAN, Molec. Immun., (19910000), vol. 28, pages 489 - 498
    - PADLAN, Molec. Immunol., (19940000), vol. 31, no. 3, page 169 217
    - KETTLEBOROUGH, C.A. et al., Protein Eng., (19910000), vol. 4, no. 7, page 773 83
    - CO, M. S. et al., J. Immunol., (19940000), vol. 152, pages 2968 - 2976
    - STUDNICKA et al., Protein Engineering, (19940000), vol. 7, pages 805 - 814
    - CATON; KOPROWSKI, Proc. Natl. Acad. Sci. USA, (19900000), vol. 87, pages 6450 - 6454
    - JAKOBOVITS et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, page 2551
    - JAKOBOVITS et al., Nature, (19930000), vol. 362, pages 255 - 258
    - BRUGGERMANN et al., Year in Immuno., (19930000), vol. 7, page 33
    - WARD et al., Nature, (19890000), vol. 341, pages 544 - 546
    - BIRD et al., Science, (19880000), vol. 242, pages 423 - 426
    - HUSTON et al., Proc. Natl. Acad. Sci. USA, (19880000), vol. 85, pages 5879 - 5883
    - GRUBER et al., J. Immunol., (19940000), vol. 152, page 5368
    - HOLLINGER et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 6444 - 6448
    - OLAFSEN et al., Protein Eng Des Sel., (20040400), vol. 17, no. 4, pages 315 - 23
    - ZAPATA et al., Protein Eng., (19950000), vol. 8, no. 10, pages 1057 - 1062
    - NERI et al., J Mol Biol., (19950000), vol. 246, pages 367 - 73
    - SCHOONJANS et al., J Immunol., (20000000), vol. 165, pages 7050 - 57
    - WILLEMS et al., J Chromatogr B Analyt Technol Biomed Life Sci., (20030000), vol. 786, pages 161 - 76
    - BIOCCA et al., EMBO J., (19900000), vol. 9, pages 101 - 108
    - COLBY et al., Proc Natl Acad Sci USA., (20040000), vol. 101, pages 17616 - 21
    - MHASHILKAR et al., EMBO J, (19950000), vol. 14, pages 1542 - 51
    - WHEELER et al., FASEB J., (20030000), vol. 17, pages 1733 - 5
    - HENG et al., Med Hypotheses., (20050000), vol. 64, pages 1105 - 8
    - CORTEZ-RETAMOZO et al., Cancer Research, (20040000), vol. 64, pages 2853 - 57
    - DESMYTER et al., J. Biol. Chem., (20010000), vol. 276, pages 26285 - 90
    - EWERT et al., Biochemistry, (20020000), vol. 41, pages 3628 - 36
    - CHOTHIA et al., J. Mol.Biol., (19870000), vol. 196, pages 901 - 917
    - SHIELDS et al., J. Biol. Chem., (20010000), vol. 276, no. 9, pages 6591 - 6604
    - KOSTELNY et al., J. Immunol., (19920000), vol. 148, pages 1547 - 1553
    - HOLLINGER et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 6444 - 48
    - ZAPATA et al., Protein Eng., (19950000), vol. 8, pages 1057 - 62
    - SILVERMAN et al., Nat Biotech, (20050000), vol. 23, no. 12, pages 1556 - 1561
    - RAZEGHIFARD et al., Current Protein & Peptide Science, (20070000), vol. 8, no. 1, pages 3 - 18
    - HOSSE et al., Protein Science, (20060000), vol. 15, pages 14 - 27
    - GILL et al., Current Opin. Biotechnol., (20060000), vol. 17, pages 653 - 658
    - SKERRA, J. Mol. Recognit., (20000000), vol. 13, pages 167 - 187
    - EGRIE et al., British J Cancer, (20010000), vol. 84, no. 1, pages 3 - 10
    - CHEMICAL ABSTRACTS, Database accession no. 501423-23-0
    - LU et al., J Biol Chem., (20040000), vol. 279, pages 2856 - 65
    - MALONEY et al., Cancer Res., (20030000), vol. 63, pages 5073 - 83
    - COHEN et al., Clinical Cancer Res., (20050000), vol. 11, pages 2063 - 73
    - THAKUR et al., Mol. Immunol., (19990000), vol. 36, pages 1107 - 1115
    - SCOTT MARKEL; DARRYL LEON, SEQUENCE ANALYSIS IN A NUTSHELL: A GUIDE TO COMMON TOOLS AND DATABASES, O'Reilly & Associates, (20030000), pages 47 - 51
    - ALTSCHUL et al., "Basic Local Alignment Research Tool", J Mol Biol, (19900000), vol. 215, pages 403 - 410
    - DOOLITTLE, R. F., "Searching through sequence databases", Met Enz., (19900000), vol. 183, pages 99 - 110
    - MEYERS; MILLER, "Optimal alignments in linear space", Comput. Applica. in Biosci, (19880000), vol. 4, doi:doi:10.1093/bioinformatics/4.1.11, pages 11 - 17, XP009076513

DOI:   http://dx.doi.org/10.1093/bioinformatics/4.1.11
    - NEEDLEMAN; WUNSCH, "A general method applicable to the search for similarities in amino acid sequence of two proteins", J Mol Biol, (19700000), vol. 48, doi:doi:10.1016/0022-2836(70)90057-4, pages 443 - 453, XP024011703

DOI:   http://dx.doi.org/10.1016/0022-2836(70)90057-4
    - SMITH; WATERMAN, "Identification of common molecular subsequences", J Mol Biol, (19810000), vol. 147, page 1950
    - ANDREWS, J., Antimicrobial Chemotherapy, (20010000), vol. 48, no. 1, pages 5 - 16
 WO2004US03742
 US20050068289
 US20050700265
 US20050713433
 US20050713478
 WO2005US46493
 US20060794771
 US20060843430
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.